Audit: QRS - Thylakoids for Health & Longevity
Audit conducted on 28/09/2026 02:48 using AI4L + evidence-mcp / GPT 6
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 90 |
| Failed | 0 |
| N/A | 4 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Dose, timing, benefits, risks, gates, and monitoring are traceable to the named ER; no additional clinical claim identified. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Uncertainty is retained for interactions, research dosing, time to effect, long-term safety, and practitioner targets; tier cards follow their specific condensation rules. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Research use remains distinct from a validated longevity regimen, and avoidance populations are retained without weakening. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Benefits, risks, interactions, and contraindications remain in their corresponding ER decision categories. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | Kresser is named only for the same glucose ranges; named medicines match the ER interaction section. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No new expert, study, or product attribution appears. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | The cautious, evidence-focused tone matches the ER Conclusion. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | The compact account presents possible appetite support alongside practical limits objectively. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Research dose and pragmatic monitoring are identified without prescribing treatment. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No validated longevity regimen or universal glucose-treatment target is implied. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | The populated content describes studies and monitoring context rather than issuing recommendations. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No direct reader address occurs in the populated content; the fixed template disclaimer is preserved. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Clinical concepts are explained in plain terms, including body mass index, appetite-hormone medicines, and average blood glucose. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Short cells, tier lists, and compact monitoring rows maintain a concise format. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | The content uses impersonal statements throughout. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | The lede explicitly addresses relevance to adults with strong nutrition and exercise habits. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Repeated monitoring and existing nutrition and exercise habits suit an engaged audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The evidence framing assumes active health optimization, with no convenience-only framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The lede limits expected value for already active adults to possible appetite support. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The sheet uses health and longevity language without anti-aging terminology. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Oral supplements, extract mass, and scientific endpoint names retain formal terminology. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All fixed section, gate, tier, and Monitoring column headings match the template. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Programmatic comparison found every template data-qrs-var anchor present, including marker_# and qualitative_item_# anchors. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Populated variables correspond to explicit checklist regions; website integration spans remain unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | No unsupported empty-state wording is introduced; absent benefit and risk tiers are hidden under the specific tier rules. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol and qualitative labels reproduce their ER bold labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Visible content labels match the source protocol, benefit, risk, or monitoring labels; no invented endpoint label was found. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators appear in the QRS content. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | A4 print sizing, 9 mm print padding, compact typography, and condensed sections support the single-page design; source-only assessment as required. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata HTML comment immediately follows the doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | A single opening and closing YAML delimiter enclose the metadata. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | The metadata is contained in an HTML comment; visible date and model are the separately required header fields. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values are trimmed; only the colon-containing duration value is quoted. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename names thylakoids_2026-0927-2228_GPT_ER.md, matching the supplied staging source. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version is 26.9.28, matching the prompt badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date uses the required 2026-0928-0240 format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname is present as GPT. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | GPT is a single word without version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname is present as GPT 6. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | GPT 6 consists of the nickname and version only. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename matches the audited HTML basename exactly. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | No unneeded quotes or surrounding whitespace appear in metadata values. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | The title uses the ER canonical_topic plus the required suffix, with ampersand entity encoding. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic matches the ER canonical_topic with ampersand entity encoding. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 09/28/2026 matches the metadata creation date. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model matches GPT 6. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Only template-defined title and subtitle content appears; website audit span remains empty. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | The opening defines plant membranes concentrated into oral spinach supplements and names appetite and weight management. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | The lede condenses the Conclusion into expected value, uncertainty, and nutrition and muscle concerns. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | Programmatic whitespace word count is 64 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | The Conclusion supports the appetite signal, inconsistent metabolic findings, active-adult relevance, uncertain safety, and unproven lifespan and disease prevention. |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | The lede contains no unexplained acronyms or specialist classifications. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No named trial, year, participant count, or p-value appears in the lede. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numerical effect size or statistical result appears in the lede. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | The avoidance list comes from the ER Key Interactions & Contraindications section. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Allergy, pregnancy and breastfeeding, children, underweight, eating disorders, undernutrition, and unintentional weight loss are retained. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Every contraindication is contained in an li element. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Contraindications contain key facts and decision qualifiers without explanatory trailing clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Supplemental-dose scope, active eating disorders, ongoing weight loss, and the body mass index threshold below 18.5 kg/m² are retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No unexplained ranking notation is carried into the avoidance list. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated because the ER names avoidance populations. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Condition does not apply: stop_items is populated. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | The interaction list comes from the ER Key Interactions & Contraindications section. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | The list covers antibiotics, other mineral-sensitive medicines, warfarin, glucose-lowering medicines, other weight interventions, nonprescription orlistat, and supplements. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Every interaction entry is contained in an li element. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Items are compact medicine or supplement lists; retained parentheticals identify product applicability and untested status rather than elaborate mechanisms. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Ciprofloxacin, doxycycline, levothyroxine, alendronate, glipizide, semaglutide, orlistat, psyllium, glucomannan, and berberine are preserved with relevant applicability qualifiers. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | No unexplained ranking notation is carried into the interaction list. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section remains populated because the ER identifies relevant interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | Condition does not apply: caution_items is populated. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three action cells derive from Therapeutic Protocol. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Research dose, meal timing, and single versus divided doses cover the three main implementation aspects. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Condition does not apply: three distinct actionable aspects are available and used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields contain source-supported dose, timing, formulation, or uncertainty information. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Both supplied time horizons are included: appetite changes within hours and body-weight evaluation over weeks to months. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | The higher-evidence appetite endpoint precedes the low-evidence body-weight endpoint. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | 🟢 | The unused third time cell is empty and hidden with display: none. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | The two used time sets match Practical Considerations and distinguish evaluation time from established weight benefit. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | Condition does not apply: the ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All benefit descriptors and their tiers derive from Expected Benefits. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | The four required benefit variables are present. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Benefit entries contain source descriptors without effect sizes, study details, or explanatory additions. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical study, effect, or mechanism content appears in the benefit entries. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The empty Medium tier is hidden with display: none and has no empty-state sentence. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All risk descriptors and their tiers derive from Potential Risks & Side Effects. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | The four required risk variables are present. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Risk entries retain source risk titles without additional study details or mechanistic explanations. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical frequency, severity, or study content appears in the risk entries. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The empty High and Medium tiers are hidden with display: none and have no empty-state sentences. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Monitoring targets, reasons, and cadence derive from Monitoring Protocol & Defining Success. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All six quantitative entries are listed: body weight and waist, fasting glucose, HbA1c, lipids, nutrient status, and warfarin clotting test. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Baseline, one-to-two-week symptoms and intake, weekly weight trends, monthly weight and waist, 12-week blood tests, and individualized warfarin checks are included with pragmatic-schedule qualification. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Qualitative assessment reproduces the Monitoring section subjective categories. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Appetite and cravings, energy and strength, and tolerance all appear with their corresponding observations. |
Issues 28/09/2026 02:48
Pass rate 100.00%. No issues found.
Issues 28/09/2026 02:43
- 1.2 / 1.3 — Missing target uncertainty qualifiers: Monitoring target cells and cadence omit “established” from the ER’s absence-of-established-target wording, including “No thylakoid-specific laboratory targets” at QRS line 637. This turns an evidence-status qualification into an unqualified absence claim.
- 2.7 — Unexplained technical drug class: Key Interactions at QRS line 579 uses “GLP-1 receptor agonists” without the ER’s plain-language explanation “appetite-hormone medicines.”
Fixes 28/09/2026 02:43
- 1.2 / 1.3 — Restored target uncertainty qualifiers: Restored “established” in the weight/waist, lipid, nutrient-status, and warfarin target cells. Changed cadence wording to the ER’s “No thylakoid-specific laboratory target is established.”
- 2.7 — Explained technical drug class: Replaced “GLP-1 receptor agonists” with the ER’s “Appetite-hormone medicines,” retaining semaglutide and the combination-uncertainty qualifier.